WO2016192560A1 - 替诺福韦单苄酯磷酰胺前药、其制备方法及应用 - Google Patents
替诺福韦单苄酯磷酰胺前药、其制备方法及应用 Download PDFInfo
- Publication number
- WO2016192560A1 WO2016192560A1 PCT/CN2016/083407 CN2016083407W WO2016192560A1 WO 2016192560 A1 WO2016192560 A1 WO 2016192560A1 CN 2016083407 W CN2016083407 W CN 2016083407W WO 2016192560 A1 WO2016192560 A1 WO 2016192560A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tenofovir
- group
- compound
- tenofovir monobenzyl
- compounds
- Prior art date
Links
- 229960004556 tenofovir Drugs 0.000 title claims abstract description 61
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 150000002148 esters Chemical class 0.000 title claims abstract description 10
- 229940002612 prodrug Drugs 0.000 title abstract description 15
- 239000000651 prodrug Substances 0.000 title abstract description 15
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 92
- 239000003814 drug Substances 0.000 claims abstract description 27
- 229940079593 drug Drugs 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 239000012453 solvate Substances 0.000 claims abstract description 10
- 208000002672 hepatitis B Diseases 0.000 claims abstract description 8
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 3
- 241000700721 Hepatitis B virus Species 0.000 claims abstract description 3
- 201000010099 disease Diseases 0.000 claims abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 3
- 230000003612 virological effect Effects 0.000 claims abstract description 3
- 208000030507 AIDS Diseases 0.000 claims abstract 2
- -1 tenofovir monobenzyl phosphate phosphoramide compound Chemical class 0.000 claims description 34
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 12
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 9
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 150000007530 organic bases Chemical class 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 2
- 229910052711 selenium Inorganic materials 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 42
- 230000000694 effects Effects 0.000 description 38
- 238000012360 testing method Methods 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 19
- LDEKQSIMHVQZJK-CAQYMETFSA-N tenofovir alafenamide Chemical compound O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 LDEKQSIMHVQZJK-CAQYMETFSA-N 0.000 description 18
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 229940126214 compound 3 Drugs 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 235000002639 sodium chloride Nutrition 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000004060 metabolic process Effects 0.000 description 9
- 238000000926 separation method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 230000000873 masking effect Effects 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 6
- 230000036436 anti-hiv Effects 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 210000005228 liver tissue Anatomy 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000003672 processing method Methods 0.000 description 3
- 231100000057 systemic toxicity Toxicity 0.000 description 3
- 229960000278 theophylline Drugs 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- QSAVEGSLJISCDF-UHFFFAOYSA-N 2-hydroxy-2-phenylacetic acid (1,2,2,6-tetramethyl-4-piperidinyl) ester Chemical compound C1C(C)(C)N(C)C(C)CC1OC(=O)C(O)C1=CC=CC=C1 QSAVEGSLJISCDF-UHFFFAOYSA-N 0.000 description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010048610 Cardiotoxicity Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- VLQHNAMRWPQWNK-UHFFFAOYSA-N benzyl 2-aminoacetate;hydron;chloride Chemical compound Cl.NCC(=O)OCC1=CC=CC=C1 VLQHNAMRWPQWNK-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 231100000259 cardiotoxicity Toxicity 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical group NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical group C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 description 2
- 229950002420 eucatropine Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- COQRGFWWJBEXRC-UHFFFAOYSA-N hydron;methyl 2-aminoacetate;chloride Chemical compound Cl.COC(=O)CN COQRGFWWJBEXRC-UHFFFAOYSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229960000381 omeprazole Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 150000003904 phospholipids Chemical group 0.000 description 2
- 125000004437 phosphorous atom Chemical group 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- IZNCNDSZTRKDQH-MERQFXBCSA-N propan-2-yl (2s)-2-amino-3-phenylpropanoate;hydrochloride Chemical compound Cl.CC(C)OC(=O)[C@@H](N)CC1=CC=CC=C1 IZNCNDSZTRKDQH-MERQFXBCSA-N 0.000 description 2
- YAQKNCSWDMGPOY-JEDNCBNOSA-N propan-2-yl (2s)-2-aminopropanoate;hydrochloride Chemical compound Cl.CC(C)OC(=O)[C@H](C)N YAQKNCSWDMGPOY-JEDNCBNOSA-N 0.000 description 2
- JURXRVIXAMNXBL-UHFFFAOYSA-N propan-2-yl 2-anilinoacetate;hydrochloride Chemical compound Cl.CC(C)OC(=O)CNC1=CC=CC=C1 JURXRVIXAMNXBL-UHFFFAOYSA-N 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- LIHHQRDTKGGDGG-UHFFFAOYSA-N 7-oxidanylchromen-2-one Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21.C1=CC(=O)OC2=CC(O)=CC=C21 LIHHQRDTKGGDGG-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- MVVBTADQVRRGCH-UHFFFAOYSA-N C1=CC(=O)OC2=CC(OCC)=CC=C21.C1=CC(=O)OC2=CC(OCC)=CC=C21 Chemical compound C1=CC(=O)OC2=CC(OCC)=CC=C21.C1=CC(=O)OC2=CC(OCC)=CC=C21 MVVBTADQVRRGCH-UHFFFAOYSA-N 0.000 description 1
- NDOGADWVVYOATI-DEQHTHAUSA-N C[C@H](C[n]1c2ncnc(N)c2nc1)OCP(NCC(OCc1ccccc1)=O)(OCc1ccccc1)=O Chemical compound C[C@H](C[n]1c2ncnc(N)c2nc1)OCP(NCC(OCc1ccccc1)=O)(OCc1ccccc1)=O NDOGADWVVYOATI-DEQHTHAUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229940126656 GS-4224 Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- IACQCQDWSIQSRP-ZCFIWIBFSA-N [(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-[hydroxy(phosphonooxy)phosphoryl]oxyphosphinic acid Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(=O)OP(O)(=O)OP(O)(O)=O)C=NC2=C1N IACQCQDWSIQSRP-ZCFIWIBFSA-N 0.000 description 1
- BQDRSOMUPPCKPB-ZCFIWIBFSA-N [(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phosphonooxyphosphinic acid Chemical group N1=CN=C2N(C[C@@H](C)OCP(O)(=O)OP(O)(O)=O)C=NC2=C1N BQDRSOMUPPCKPB-ZCFIWIBFSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N anhydrous gallic acid Natural products OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940124405 anti-hepatitis b virus drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 1
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000012402 patch clamp technique Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- UBKCIXXGQRZHRO-UHFFFAOYSA-N propan-2-yl 2-aminoacetate;hydrochloride Chemical compound Cl.CC(C)OC(=O)CN UBKCIXXGQRZHRO-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012284 sample analysis method Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- ZAVXXBAIPSQJGS-UHFFFAOYSA-B tetracalcium;tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ZAVXXBAIPSQJGS-UHFFFAOYSA-B 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Definitions
- the invention belongs to the field of medicinal chemistry, and particularly relates to a novel tenofovir monobenzyl ester phosphoramide compound or hydrate, solvate, pharmaceutically acceptable salt or single chiral isomer thereof, and preparation method thereof and medicament thereof Application on.
- Tenofovir is a water-soluble oral anti-HIV and anti-hepatitis B virus drug that is stable in the stomach, enters the body with blood after intestinal absorption, and is evenly distributed in human tissues, less than 20%. Metabolism and activation into tenofovir parent drug by the action of enzyme ester and double-phosphorylation to form tenofovir diphosphate after the onset, the other about 80% of the original form of urine excreted.
- a strategy of adding a masking group to the tenofovir phosphate group to form a fat-soluble prodrug is currently adopted, in which one masking group forms a phosphoramide structure with a phosphate group, and another group Compounds that form phospholipid structures with phosphate groups have been shown to have lymphatic and liver tissue targeting effects.
- the ester-forming group includes various aromatic rings and aromatic heterocyclic rings, particularly substituted or unsubstituted phenyl groups (CN201310041647.4, WO02082841), and the patent (CN01813161) discloses a compound GS-7340 obtained by using such a prodrug strategy.
- liver-targeting properties compared to tenofovir (TDF), while activity enhances toxicity.
- TDF tenofovir
- the metabolically active parent drug tenofovir can still be produced in the blood, thereby bringing about certain systemic toxicity, and the phenol itself produced by metabolism is also highly toxic.
- a substituted benzylic tenofovir prodrug compound on a benzene ring has been shown to have liver-targeting activity.
- Patent US20130210757, CN201380030061.6 discloses a masking group for amino acid esters and phosphoric acid groups to form phosphoramide, a masking A benzyl group having a group substituted with an electron-donating group such as a methyl group on the benzene ring or a p-phosphate group forms a substituted benzyl ester on the benzene ring.
- an electron-donating group such as a methyl group on the benzene ring or a p-phosphate group
- the masking group o-methylbenzyl group in the disclosed compound structure has high group leaving activity, low stability in blood enzyme ester metabolism, and the target group is relatively easy to fall off and cause activity in blood.
- the relative increase of the parent drug and the active parent drug in the liver are relatively reduced, thereby affecting the activity and systemic toxicity.
- the present invention provides a class of tenofovir monobenzyl phosphate phosphorus-amide compounds which are unsubstituted on a benzylbenzene ring, a preparation method thereof and a lymphoid target thereof Compared with GS-7340 and Compound 7, this prodrug is more stable to the enzyme ester than the GS-7340 and Compound 7, further enhancing the systemic stability and liver targeting resistance of tenofovir analogs. The role of the virus.
- the inventors of the present invention invented a class of unsubstituted tenofovir monobenzyl phosphate phosphoramides on benzylbenzene rings, and unexpectedly found that the compounds of the invention can be metabolized into the active parent drug tenofovir in cellular experiments. (TFV), thus having antiviral activity.
- TBV tenofovir
- mice can be enriched in the liver and effectively metabolized into the active product tenofovir after gavage, and the compounds of the invention are more active against HBV than in the prior art, or in plasma. It is more stable and its metabolic fragments are safer, thus reducing systemic side effects caused by plasma metabolism.
- the present invention provides a tenofovir monobenzyl phosphate phosphoramide compound having the general formula X, a hydrate, a solvate thereof, a pharmaceutically acceptable salt or a resolved single isomer thereof,
- Z is selected from the group consisting of O, S, Se, NH- or -CH 2 -,
- R 1 , R 2 , R 3 , R 4 , R 5 are each independently selected from H, a substituted or unsubstituted C 1 -C 10 linear hydrocarbon group, a C 3 -C 10 branched hydrocarbon group, a C 3 -C 10 ring a hydrocarbyl group, a C 6 -C 10 aromatic hydrocarbon group or a heteroaryl group, wherein the substitution is one to three heteroatoms independently selected from O, S, N, Se, or R 1 and R 2 , R 1 and R 3 R 2 and R 3 together with the moiety linking them form a substituted or unsubstituted 3-8 membered ring.
- Z is selected from O or S
- R 1 , R 2 , R 3 , R 4 , R 5 are each independently selected from H, a substituted or unsubstituted C 1 -C 6 linear hydrocarbon group, a C 3 -C 6 branched hydrocarbon group, a C 3 -C 6 ring Hydrocarbyl group, C 6 -C 10 aromatic hydrocarbon group or heteroaryl group.
- Z is selected from O,
- R 1 , R 2 , R 3 , R 4 , and R 5 are each independently selected from H, a substituted or unsubstituted C 1 -C 6 linear hydrocarbon group, a C 3 -C 6 branched hydrocarbon group, and a C 6 -C 10 aromatic group. Hydrocarbyl group.
- the tenofovir monobenzyl phosphate phosphoramide compound of the present invention is selected from the compounds of Table 1.
- the stereochemistry of prodrugs can affect their metabolic and antiviral activity in target tissues, and the chiral moiety is on the phosphorus atom and is also found in its masking group amino acids. For example, an amino acid having a natural configuration has a better metabolic activity, and an isomer having a P atom configuration of S in the compound 3 has a stronger activity. If the chiral sites are impure, chiral enrichment of these diastereomers or racemates is required, making the screening results more meaningful. Purification by chiral resolution affords the formation of a single isomer at the above chiral center such that each test compound is essentially a single chiral compound.
- a substantially unitary compound or chiral enrichment means that the desired stereoisomer constitutes more than about 60% by weight of the compound, by more than 80%, preferably more than 95%.
- the invention is separated by reverse phase column separation or chiral column separation, and the mobile phase is an aqueous acetonitrile solution.
- Another object of the present invention is to provide a process for preparing a tenofovir monobenzyl phosphate phosphoramide compound, which comprises the following steps:
- tenofovir is reacted with benzyl halide or benzyl alcohol in the presence of a base to give a tenofovir monobenzyl ester intermediate;
- the base may be various inorganic or organic bases, preferably an organic base; and the terminal NH group-containing compound in step B is preferably an amino acid ester compound or an amino acid.
- An amide compound is preferably an amino acid ester compound or an amino acid.
- DIPEA diisopropylethylamine
- benzyl bromide or benzyl alcohol is sequentially added to the tenofovir acetonitrile suspension, and the mixture is heated to 50 ° C - 80 ° C, stirred under heating for 2-24 hours, and pyridine is added.
- the invention further comprises a method for chiral separation of the compound, HPLC preparative column separation (preparation column: C18, mobile phase: 10%-50% aqueous acetonitrile (V/V)) or chiral column separation to collect the eluent for each retention time. Dry to obtain each chiral isomer.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising the tenofovir monobenzyl ester phosphate amide compound, or a hydrate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof Or a single isomer of its resolution.
- the pharmaceutically acceptable salt of the compound of the present invention can be obtained by acid-base neutralization using conventional techniques in the chemical field as needed. If the compound of the present invention is reacted with sulfuric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, tartaric acid, fumaric acid, maleic acid, citric acid, acetic acid, formic acid, methanesulfonic acid, p-toluenesulfonic acid, oxalic acid or succinic acid, the corresponding reaction is obtained. Salt.
- the compound of the present invention may be reacted with sodium hydroxide, potassium hydroxide, cesium hydroxide or the like, an alkali metal carbonate such as sodium carbonate, calcium carbonate or the like to obtain the corresponding salt.
- the reaction can be carried out in a solvent such as water or an organic solvent such as ethanol, tetrahydrofuran, dioxane, ethylene glycol, acetic acid or the like, or a mixture of such an organic solvent and water.
- the reaction can also be carried out without any solvent, if necessary.
- the pharmaceutical composition of the present invention is preferably in the form of a unit dosage of a pharmaceutical preparation which can be formulated into any pharmaceutically acceptable dosage form, which is selected from the group consisting of: tablets, sugar-coated tablets, film-coated tablets, Enteric coated tablets, capsules, hard capsules, soft capsules, oral liquids, buccal preparations, granules, suspensions, solutions, injections, suppositories, ointments, plasters, creams, sprays, Patch.
- Preferred are oral formulations, and tablets and capsules are most preferred.
- composition of the present invention further comprises a pharmaceutically acceptable carrier.
- the pharmaceutical preparation can be prepared by a conventional technique of formulation, such as the tenofovir monobenzyl phosphate phosphoramide compound of the present invention, or a hydrate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof
- the single isomer is mixed with a pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier includes, but is not limited to, mannitol, sorbitol, sorbic acid or potassium salt, sodium metabisulfite, sodium hydrogen sulfite, sodium thiosulfate, cysteine hydrochloride, thioglycolic acid, methionine, Vitamin A, Vitamin C, vitamin E, vitamin D, azone, EDTA disodium, EDTA calcium sodium, monovalent alkali metal carbonate, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulfuric acid, phosphoric acid, amino acid, rich Horse acid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivatives, cellulose and its derivatives, Alginate, gelatin, polyvinylpyrrolidone, glycerin, propylene glyco
- a unit dose of the medicament may contain 0.1 to 1000 mg of the pharmaceutically active substance of the present invention, and the balance is a pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier may be from 0.1 to 99.9% by weight based on the total weight of the formulation.
- the pharmaceutical composition of the present invention determines the usage amount according to the condition of the patient at the time of use.
- the present invention finally provides the tenofovir monobenzyl phosphate phosphoramide compound, or a hydrate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a resolved single isomer thereof, in the preparation of a treatment
- the use in a medicament for a viral infectious disease is preferably used in the preparation of a medicament for treating an HIV infection or a disease caused by hepatitis B or hepatitis B virus.
- DIPEA (10 mmol) and benzyl bromide (5 mmol) were added to a suspension of tenofovir (5 mmol) in acetonitrile (20 mL). The mixture was heated to 80 ° C and stirred for 16 hr. Add pyridine (20 mL) to dissolve, and then add triethylamine (5 mL) and glycine isopropyl ester hydrochloride (10 mmol), and then stir to 50 ° C for 30 minutes, then add triphenylphosphine (15 mmol) and 2 at this temperature. 2'-Dithiodipyridine (15 mmol), and the mixture was stirred at 50 ° C for 3 hours, and then dried under reduced pressure. The residue was purified by silica gel chromatography eluting elut The yield was 48%.
- DIPEA (10 mmol) and benzyl bromide (5 mmol) were added to a suspension of tenofovir (5 mmol) in acetonitrile (20 mL). The mixture was heated to 80 ° C and stirred for 16 hr. Add pyridine (20 mL) to dissolve, and then add triethylamine (5 mL) and glycine methyl ester hydrochloride (10 mmol), and then stir to 50 ° C for 30 minutes, then add triphenylphosphine (15 mmol) and 2 at this temperature. 2'-Dithiodipyridine (15 mmol) was stirred at 50 ° C for 3 hours and then dried under reduced pressure. The residue was purified by silica gel chromatography eluting elut The yield was 57%.
- DIPEA (10 mmol) and benzyl bromide (5 mmol) were added to a suspension of tenofovir (5 mmol) in acetonitrile (20 mL). The mixture was heated to 80 ° C and stirred for 16 hr. Add pyridine (20 mL) to dissolve, and then add triethylamine (5 mL) and L-phenylalanine isopropyl ester hydrochloride (10 mmol), and then stir to 50 ° C for 30 minutes, then add triphenylphosphine at this temperature. (15 mmol) and 2,2'-dithiodipyridine (15 mmol) were stirred at 50 ° C for 3 hours and then dried under reduced pressure. The residue was purified by silica gel chromatography eluting elut The yield was 61%.
- DIPEA (10 mmol) and benzyl bromide (5 mmol) were added to a suspension of tenofovir (5 mmol) in acetonitrile (20 mL). The mixture was heated to 80 ° C and stirred for 16 hr. Add pyridine (20 mL) to dissolve, and then add triethylamine (5 mL) and benzyl glycinate hydrochloride (10 mmol), and then stir to 50 ° C for 30 minutes, then add triphenylphosphine (15 mmol) and 2 at this temperature. 2'-Dithiodipyridine (15 mmol) was stirred at 50 ° C for 3 hours and then dried under reduced pressure. The residue was purified by silica gel chromatography eluting elut The yield was 58%.
- HPLC reversed-phase column separation or HPLC chiral column separation Compound 2 (200 mg) of Example 2 was isolated by HPLC (preparation column: Diamonsil C18, 5 ⁇ m, 150 ⁇ 21.1 mm; mobile phase: 20% aqueous acetonitrile (V) /V)) Compound 2a (83 mg; retention time 14 min) and compound 2b (90 mg; retained) after isocratic elution Time 17min).
- Test Example The beneficial effects of the present invention are exemplified by the following tests
- the prodrug compounds For prodrug compounds, the most critical is the stability of the prodrug in the system and the metabolic activity in the target organ part, the higher the stability in the system (gastrointestinal, blood, etc.), in the target organ (lymph, The higher the activity of metabolizing into a parent drug in the liver, the lower the toxicity of the compound and the higher the drug effect.
- the prodrugs such as the compound of the present invention and the reference compound were all metabolized to the active parent drug tenofovir (TFV) to exert an antiviral action.
- the currently similar prodrug compounds are compounds of the CN201380030061.6 claim (abbreviated as compound 7 and its single chiral isomers 7a, 7b) and Gilead recently applied to the FDA for the market treatment of hepatitis B drug TAF (GS-7340). It contains the same parent drug structure as the compound of the present invention, but the liver targeting fragment is different.
- the compounds of the present invention are advantageous in that the activity is higher or the system is more stable and the system is less toxic. Further, the benzoic acid compound produced by the metabolism of the compound of the present invention is relatively safe relative to GS-7340, overcoming the GS-7340. The release of toxic phenol has the advantage of superior toxicity and lower toxicity. Further, in contrast to the compound of the CN201380030061.6 claim, since the compound target group benzyl group of the present invention is more stable than o-methylbenzyl group, the benzyl detachment activity is lower in blood enzyme ester metabolism, and thus is in the blood. The active parent drug is relatively reduced, and the active parent drug in the liver is relatively increased, thereby exhibiting better activity. The benzyl group of the present invention has less toxicity after detachment, and has superior system stability and lower toxicity. details as follows:
- Test Example 1 Comparison of anti-HBV activity and cytotoxicity at the cellular level
- HepG2.2.15 cells (4 x 10 4 cells/well) were seeded into 96-well plates and incubated overnight at 37 ° C, 5% CO 2 . The next day, fresh culture medium containing different concentrations of compounds was added to the culture wells. The compound arrangement is shown in Table 2. On the fifth day, the old culture solution in the culture well was aspirated and fresh culture medium containing different concentrations of the compound was added. On the eighth day, the supernatant in the culture well was collected for extracting HBV DNA from the supernatant. The qPCR assay was used to detect the HBV DNA content in the supernatant of HepG2.2.15.
- %Inh. [(HBV quantity of DMSO control-HBV quantity of sample)/HBV quantity of DMSO control] ⁇ 100%
- %cell viability (fluorescence of sample–fluorescence of medium control)/(fluorescence of DMSO control-fluorescence of medium control) ⁇ 100%
- test compounds 3a, 3b showed better anti-hepatitis B virus activity, EC 50 value below 10 nM, 4 test compounds 1b, 2a 5a, 5b anti-hepatitis B virus activity is relatively weak, EC 50 value between 200nM-1000nM; the other two test compounds 1a, 2a anti-hepatitis B virus activity EC 50 value is higher than the maximum test concentration of 1000nM.
- the compounds 1, 2, 4, 5, and 6 of the present invention are structurally similar to the compound 3, and thus have similar pharmacodynamic effects.
- Test Example 2 Comparison of cell level anti-HBV activity and cytotoxicity
- the compounds 3a and 3b of the present invention showed better anti-hepatitis B virus activity, and the effects were remarkably superior to those of the reference compounds 7a, 7b and GS-7340. Both had no significant effect on HepG2.2.15 cytotoxicity (CC 50 >100 ⁇ M)
- Test Example 3 Cell level anti-HIV activity and cytotoxicity test
- MT-4 cells were infected with 24 TCID50 HIV-1 IIIB/1x105 cells (2.4 TCID50/well) for 1 hour at 37 ° C and seeded in 96-well plates containing different concentrations of compounds (4 ⁇ 10). 4 cells/well), cultured at 37 ° C, 5% CO 2 for 5 days. Activity was calculated EC 50 value was determined by CellTiter Glo.
- Compounds 3a and 3b were more active against HIV than 7b and GS-7340; while 3a and 3b were less toxic to MT-4 cells than GS-7340 and 7b.
- CHO cells stably expressing hERG potassium channels were obtained from AViva Biosciences, and the cells were incubated at 37 ° C, 5% CO 2 , constant humidity.
- the compound and the positive control compound amitriptyline (Amitriptyline, Sigma-Aldrich, BCBJ8594V) were diluted in 100% dimethyl sulfoxide (DMSO) and the final concentration of DMSO in the extracellular fluid was not higher than 0.30%. Stand by at -20 °C.
- the compounds were tested on a Multiclamp patch-clamp amplifier at room temperature using whole-cell patch clamp technique.
- the output signals were digitized using a DIgiDAta 1440A/D-D/A plate, and the Pclamp10 software was used for recording control.
- the minimum sealing resistance was set to 500 MOhms and the minimum specific hERG current was 0.4 nA for quality control.
- ICR mice Male, weight 30 ⁇ 5 g, purchased from Vitallihua Animal Center
- 12 h 12 h before dosing, and given free water during fasting.
- 30 mg of compound 3 was accurately weighed, dissolved in 100 ⁇ L of 75% ethanol, further added with physiological saline to 6 mL, vortexed and mixed, and ultrasonicated for use.
- the tenofovir prodrug was administered at a dose of 50 mg/kg and the dose was 10 mL/kg.
- Sample collection protocol 0.5 mL of blood was taken from the eyelids at 15 min, 30 min, 1 h and 3 h after intragastric administration. The liver tissue was washed and weighed. The liver was added to the physiological saline homogenate at a ratio of 1:1. Store in a 40 ° C refrigerator for testing.
- internal standard 200 ng/ml theophylline
- internal standard 200 ng/ml theophylline
- Thermo TSQquantum LC/MS and column Thermo Hypersil GOLD (2.1 ⁇ 150mm), internal standard Theophylline, HPLC-MS injection, gradient elution analysis, recording internal standard, compound 1 and metabolite tenofovir
- the retention time and peak area of (TFV) were analyzed by SRM quantitative detection method.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (10)
- 根据权利要求1所述的替诺福韦单苄酯磷酰胺类化合物,其中,Z选自O或S,R1,R2,R3,R4,R5分别独立地选自H,取代或未取代的C1-C6直链烃基、C3-C6支链烃基、C3-C6环烃基、C6-C10芳香烃基或杂芳基。
- 根据权利要求2所述的替诺福韦单苄酯磷酰胺类化合物,其中,Z选自O,R1,R2,R3,R4,R5分别独立地选自H,取代或未取代的C1-C6直链烃基、C3-C6支链烃基、C6-C10芳香烃基。
- 根据权利要求1~5任一所述的替诺福韦单苄酯磷酰胺类化合物的制备方法,其特征在于,包括如下步骤:A:替诺福韦在碱的存在下与卤化苄或苄醇反应得到替诺福韦单苄酯中间体;B:替诺福韦单苄酯中间体与与各种含末端NH基团的化合物,优选氨基酸酯类化合物、氨基酸酰胺类化合物反应生成本发明的替诺福韦单苄酯磷酰胺类化合物。
- 根据权利要求6任一所述的替诺福韦单苄酯磷酰胺类化合物的制备方法,其中,步骤A中替诺福韦优选与苄溴或苄醇进行反应,碱可以是各种无机或有机碱,优选有机碱。
- 一种药物组合物,其特征在于,所述药物组合物含有权利要求1-4任一项所述的替诺福韦单苄酯磷酰胺类化合物、或其水合物、或其溶剂化物、或其药学上可接受的盐或其拆分的单一异构体;其中,所述药物组合物还含有药学上可接受的载体。
- 根据权利要求1~5任一所述替诺福韦单苄酯磷酰胺类化合物、或其水合物、或其溶剂化物、或其药学上可接受的盐或其拆分的单一异构体在制备治疗病毒感染性疾病的药物中的用途。
- 根据权利要求9所述的替诺福韦单苄酯磷酸胺类化合物、或其水合物、或其溶剂化物、或其药学上可接受的盐或其拆分的单一异构体在制备治疗艾滋病感染或乙型肝炎或者乙肝病毒引起的疾病的药物中的用途。
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020177037627A KR20180016437A (ko) | 2015-05-29 | 2016-05-26 | 테노포비르 모노벤질 에스테르 포스파미드 전구약물, 이의 제조방법 및 용도 |
EP16802483.4A EP3305795B1 (en) | 2015-05-29 | 2016-05-26 | Tenofovir monobenzyl ester phosphamide prodrug, preparation method and use thereof |
AU2016270101A AU2016270101B2 (en) | 2015-05-29 | 2016-05-26 | Tenofovir monobenzyl ester phosphamide prodrug, preparation method and use thereof |
RU2017145357A RU2719594C2 (ru) | 2015-05-29 | 2016-05-26 | Пролекарство на основе фосфамида монобензилового сложного эфира тенофовира, способ его получения и применение |
SG11201709786WA SG11201709786WA (en) | 2015-05-29 | 2016-05-26 | Tenofovir monobenzyl ester phosphamide prodrug, preparation method and use thereof |
US15/577,956 US10233202B2 (en) | 2015-05-29 | 2016-05-26 | Tenofovir monobenzyl ester phosphamide prodrug, preparation method and use thereof |
CN201680031443.4A CN107709340B (zh) | 2015-05-29 | 2016-05-26 | 替诺福韦单苄酯磷酰胺前药、其制备方法及应用 |
ES16802483T ES2806726T3 (es) | 2015-05-29 | 2016-05-26 | Profármaco tenofovir éster monobencílico fosfamida, método de preparación y uso del mismo |
MYPI2017704555A MY191515A (en) | 2015-05-29 | 2016-05-26 | Tenofovir monobenzyl ester phosphamide prodrug, preparation method and use thereof |
CA2987473A CA2987473A1 (en) | 2015-05-29 | 2016-05-26 | Tenofovir monobenzyl ester phosphamide prodrug, preparation method and use thereof |
JP2017561871A JP6679624B2 (ja) | 2015-05-29 | 2016-05-26 | テノホビルモノベンジルエステルホスファミドプロドラッグ、その調製方法及び使用 |
IL255892A IL255892B (en) | 2015-05-29 | 2017-11-26 | Tenofovir monobenzyl ester phosphamide prodrug, preparation method and their use |
HK18106521.5A HK1246799A1 (zh) | 2015-05-29 | 2018-05-18 | 替諾福韋單苄酯磷酰胺前藥、其製備方法及應用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510290530 | 2015-05-29 | ||
CN201510290530.9 | 2015-05-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016192560A1 true WO2016192560A1 (zh) | 2016-12-08 |
Family
ID=57440060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2016/083407 WO2016192560A1 (zh) | 2015-05-29 | 2016-05-26 | 替诺福韦单苄酯磷酰胺前药、其制备方法及应用 |
Country Status (15)
Country | Link |
---|---|
US (1) | US10233202B2 (zh) |
EP (1) | EP3305795B1 (zh) |
JP (1) | JP6679624B2 (zh) |
KR (1) | KR20180016437A (zh) |
CN (2) | CN106188139B (zh) |
AU (1) | AU2016270101B2 (zh) |
CA (1) | CA2987473A1 (zh) |
ES (1) | ES2806726T3 (zh) |
HK (1) | HK1246799A1 (zh) |
IL (1) | IL255892B (zh) |
MY (1) | MY191515A (zh) |
RU (1) | RU2719594C2 (zh) |
SG (1) | SG11201709786WA (zh) |
TW (1) | TWI692479B (zh) |
WO (1) | WO2016192560A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109485676A (zh) * | 2017-12-21 | 2019-03-19 | 深圳市塔吉瑞生物医药有限公司 | 用于抗病毒的新型核苷类逆转录酶抑制剂 |
JP2020504733A (ja) * | 2016-12-22 | 2020-02-13 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | テノホビルの抗ウイルス性脂肪族エステルプロドラッグ |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105983016B (zh) | 2015-03-23 | 2023-08-11 | 天士力医药集团股份有限公司 | 一种含有水飞蓟宾的药物组合 |
CN106188139B (zh) * | 2015-05-29 | 2020-02-18 | 江苏天士力帝益药业有限公司 | 替诺福韦单苄酯磷酸酰胺前药、其制备方法及应用 |
JP2021528363A (ja) * | 2018-06-12 | 2021-10-21 | シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド | ホスホンアミドエステル化合物、その塩、その関連する結晶体、その製造方法及びその使用 |
CN111018916B (zh) * | 2019-12-30 | 2022-04-29 | 天津天士力圣特制药有限公司 | 一种替诺福韦苯基烷基酯膦酰胺前体的合成方法 |
CN111116655B (zh) * | 2019-12-30 | 2022-10-25 | 天津天士力圣特制药有限公司 | 一种高光学纯度替诺福韦苄酯膦酰胺前体药物的制备方法 |
CN114262348A (zh) * | 2020-09-16 | 2022-04-01 | 上海本仁科技有限公司 | 环状核苷磷酸酯类化合物及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009005693A1 (en) * | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Novel hiv reverse transcriptase inhibitors |
CN103435672A (zh) * | 2013-04-25 | 2013-12-11 | 刘沛 | 含有取代苄基的新型核苷磷酸酯前药的结构与合成 |
CN104640444A (zh) * | 2012-06-16 | 2015-05-20 | 南京迈勒克生物技术研究中心 | 双肝脏靶向氨基磷酸酯和氨基膦酸酯前药 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP2003002716A0 (en) * | 2000-06-13 | 2003-06-30 | Shionogi & Co | Medicinal compositions containing propenone derivatives. |
AU2001282941C1 (en) | 2000-07-21 | 2016-12-22 | Gilead Sciences, Inc. | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
CN1465582A (zh) * | 2002-07-01 | 2004-01-07 | 中国人民解放军军事医学科学院放射医 | 核苷酸类似物、含它的药物组合物及其用途 |
US9095599B2 (en) * | 2011-01-03 | 2015-08-04 | Nanjing Molecular Research, Inc. | O-(substituted benzyl) phosphoramidate compounds and therapeutic use |
US9156874B2 (en) * | 2011-01-03 | 2015-10-13 | Nanjing Molecular Research, Inc. | Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs |
CN107312039B (zh) * | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
CN106188139B (zh) * | 2015-05-29 | 2020-02-18 | 江苏天士力帝益药业有限公司 | 替诺福韦单苄酯磷酸酰胺前药、其制备方法及应用 |
-
2016
- 2016-05-25 CN CN201610353768.6A patent/CN106188139B/zh active Active
- 2016-05-26 KR KR1020177037627A patent/KR20180016437A/ko not_active Application Discontinuation
- 2016-05-26 JP JP2017561871A patent/JP6679624B2/ja not_active Expired - Fee Related
- 2016-05-26 WO PCT/CN2016/083407 patent/WO2016192560A1/zh active Application Filing
- 2016-05-26 US US15/577,956 patent/US10233202B2/en not_active Expired - Fee Related
- 2016-05-26 EP EP16802483.4A patent/EP3305795B1/en active Active
- 2016-05-26 AU AU2016270101A patent/AU2016270101B2/en not_active Ceased
- 2016-05-26 SG SG11201709786WA patent/SG11201709786WA/en unknown
- 2016-05-26 CN CN201680031443.4A patent/CN107709340B/zh active Active
- 2016-05-26 RU RU2017145357A patent/RU2719594C2/ru active
- 2016-05-26 MY MYPI2017704555A patent/MY191515A/en unknown
- 2016-05-26 ES ES16802483T patent/ES2806726T3/es active Active
- 2016-05-26 CA CA2987473A patent/CA2987473A1/en not_active Abandoned
- 2016-05-27 TW TW105116542A patent/TWI692479B/zh not_active IP Right Cessation
-
2017
- 2017-11-26 IL IL255892A patent/IL255892B/en active IP Right Grant
-
2018
- 2018-05-18 HK HK18106521.5A patent/HK1246799A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009005693A1 (en) * | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Novel hiv reverse transcriptase inhibitors |
CN104640444A (zh) * | 2012-06-16 | 2015-05-20 | 南京迈勒克生物技术研究中心 | 双肝脏靶向氨基磷酸酯和氨基膦酸酯前药 |
CN103435672A (zh) * | 2013-04-25 | 2013-12-11 | 刘沛 | 含有取代苄基的新型核苷磷酸酯前药的结构与合成 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020504733A (ja) * | 2016-12-22 | 2020-02-13 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | テノホビルの抗ウイルス性脂肪族エステルプロドラッグ |
CN109485676A (zh) * | 2017-12-21 | 2019-03-19 | 深圳市塔吉瑞生物医药有限公司 | 用于抗病毒的新型核苷类逆转录酶抑制剂 |
JP2021506938A (ja) * | 2017-12-21 | 2021-02-22 | 深▲チェン▼市塔吉瑞生物医薬有限公司Shenzhen TargetRx, Inc. | 新規抗ウイルス性ヌクレオシド系逆転写酵素阻害剤 |
JP7076158B2 (ja) | 2017-12-21 | 2022-05-27 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | 新規抗ウイルス性ヌクレオシド系逆転写酵素阻害剤 |
CN109485676B (zh) * | 2017-12-21 | 2022-07-15 | 深圳市塔吉瑞生物医药有限公司 | 用于抗病毒的新型核苷类逆转录酶抑制剂 |
US11447512B2 (en) | 2017-12-21 | 2022-09-20 | Shenzhen Targetrx, Inc. | Antiviral nucleoside reverse transcriptase inhibitor |
Also Published As
Publication number | Publication date |
---|---|
ES2806726T3 (es) | 2021-02-18 |
EP3305795A1 (en) | 2018-04-11 |
US10233202B2 (en) | 2019-03-19 |
EP3305795A4 (en) | 2019-02-06 |
IL255892B (en) | 2020-11-30 |
JP2018517698A (ja) | 2018-07-05 |
RU2017145357A (ru) | 2019-07-01 |
CN107709340B (zh) | 2020-03-17 |
AU2016270101B2 (en) | 2020-01-23 |
EP3305795B1 (en) | 2020-05-06 |
RU2017145357A3 (zh) | 2019-09-04 |
CA2987473A1 (en) | 2016-12-08 |
KR20180016437A (ko) | 2018-02-14 |
MY191515A (en) | 2022-06-28 |
US20180127445A1 (en) | 2018-05-10 |
CN107709340A (zh) | 2018-02-16 |
TW201702246A (zh) | 2017-01-16 |
TWI692479B (zh) | 2020-05-01 |
HK1246799A1 (zh) | 2018-09-14 |
CN106188139A (zh) | 2016-12-07 |
JP6679624B2 (ja) | 2020-04-15 |
RU2719594C2 (ru) | 2020-04-21 |
SG11201709786WA (en) | 2017-12-28 |
CN106188139B (zh) | 2020-02-18 |
IL255892A (en) | 2018-01-31 |
AU2016270101A1 (en) | 2017-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107709340B (zh) | 替诺福韦单苄酯磷酰胺前药、其制备方法及应用 | |
BR112015003778B1 (pt) | Profármaco de tenofovir, composição farmacêutica, e seus usos | |
CN106167504A (zh) | 非环核苷磷酰胺d‑氨基酸酯衍生物及其盐的制备以及在抗病毒方面的应用 | |
ES2639863A1 (es) | Compuestos para el tratamiento de enfermedades causadas por la acumulación de oxalato | |
CN109071588B (zh) | 尿苷类磷酰胺前药、其制备方法及其在医药上的应用 | |
US11130766B2 (en) | Deuterated thienopiperidine derivatives, manufacturing method, and application thereof | |
CN111484541B (zh) | 双核苷酸前体药物及其制备方法 | |
CN110092799B (zh) | 一种环状化合物、其制备方法和应用 | |
CN101768155B (zh) | 一类含(氨甲基-五元芳香杂环-4-羰基)-吡咯烷-2-羧酸的衍生物、其制备方法和用途 | |
JPH0395166A (ja) | イソキサゾロン誘導体含有脳機能改善剤 | |
KR20090048496A (ko) | 개선된 생체이용률을 갖는 아미노이소퀴놀린 트롬빈 저해제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16802483 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 255892 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11201709786W Country of ref document: SG |
|
ENP | Entry into the national phase |
Ref document number: 2987473 Country of ref document: CA Ref document number: 2017561871 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15577956 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2016270101 Country of ref document: AU Date of ref document: 20160526 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20177037627 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017145357 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016802483 Country of ref document: EP |